Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc. [The Motley Fool]
Bellicum Pharmaceuticals, Inc. (BLCM)
Last bellicum pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.bellicum.com/investor-overview
Company Research
Source: The Motley Fool
Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner? It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals ( NASDAQ:BLCM ) and Alnylam Pharmaceuticals ( NASDAQ:ALNY ) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion. Market caps don't mean a thing when evaluating future prospects for biotechs, though. Which of these stocks is the better pick for investors with a long-term perspective? Here's how Bellicum Pharmaceuticals and Alnylam Pharmaceuticals compare. Image source: Getty Images. The case for Bellicum At the moment, there's one overriding reason why investors might want to consider buying Bellicum stock: the biotech's lead candidate, BPX-501. The drug is in phase 3 clinical studies in both the U.S. and Europe targeting
Show less
Read more
Impact Snapshot
Event Time:
BLCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCM alerts
High impacting Bellicum Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BLCM
News
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
BLCM
Sec Filings
- 3/1/24 - Form 15-12G
- 2/27/24 - Form EFFECT
- 2/27/24 - Form EFFECT
- BLCM's page on the SEC website